Table 3.

Results of univariate analysis for survival

Characteristics No.patients Median survival (mos) 95% CI P3-150Corrected P3-151
Age (years)  
 <65  74  87.2 (64.5-123.9)  
 ≥65  158  51.1  (42.3-63.0)  .0009 .022  
Sex 
 Female  67  107.9  (55.1-150.9) 
 Male  165  58.7  (48.1-65.7)  .0001 
Hepatomegaly 
 Absent  183  66.0  (58.7-72.5) 
 Present  49  34.5  (27-52.7)  .0025 
Splenomegaly3-152 
 Absent  179  64.5  (55.1-70.7) 
 Present  51  51.1  (36.5-69.9)  .15  
Monoclonal IgM (g/L) 
 Lower than 25  92  68.0  (55.1-96.9)  
 At least 25  140  59.4  (49.3-66.8)  .023  .294 
Hemoglobin level (g/dL)3-152 
 Lower than 12  145  49.3 (37.8-59.4)  
 At least 12  73  107.5  (73.3-126.3) .0001  .003  
Platelets (109/L)3-152 
 Fewer than 150  46  40.2  (33.3-51.1)  
 At least 150  167  67.2 (59.4-76.6)  .0001  .003  
Leukocytes (109/L)3-152 
 Fewer than 4  16  41.7 (13.1-58.2)  
 At least 4 and fewer than 10  176  65.7 (55.1-73.3)  
 At least 10  32  50.7  (30.4-69.3) .0057  .250  
PMN count (109/L)3-152 
 Fewer than 1.5  17  28.1  (4.7-49.3)  
 1.5 to 10  193 64.6  (58.7-72.3)  
 More than 10  6  30.4 (7.5-71.3)  .0006  .070  
No. cytopenia3-152 
 0  57 123.9  (73.4-150.9)  
 1  105  60.7  (42.9-67.7) 
 2 or 3  41  34.5  (23.5-48.1)  .0001  
Serum albumin (g/L)3-152 
 Lower than 40  135  49.3  (40.2-58.6) 
 At least 40  59  107.5  (73.3-131.7)  .0001  .003 
β2 microglobulin3-152 
 Up to 3 mg/L  12 111.6  (37.6-126.3)  
 More than 3 mg/L  30  51.1 (42.3-67.7)  .038  
Plasma volume3-152 
 Less than 50 mL/kg 10  150.9  (15-NA)  
 More than 50 mL/kg  46  38.9 (28.1-51.5)  .0128  
Binet staging3-152 
 A  83  87.2 (67.7-122.4)  
 B  28  52.7  (31.6-95.3)  
 C  84 37.6  (28-51.7)  .0001  
Rai staging3-152 
 0 or 1  53 111.6  (72.3-142.5)  
 2  28  67.2  (38.9-122.4) 
 3 or 4  142  51.7  (37.6-61.8)  .0001  
Gobbi staging3-152 
 Low risk  109  72.3  (64.6-90.4)  
 High risk  53  48.3  (33.2-58.8)  .004  
Treatment  
 No initial therapy  65  66.8  (48.3-118.4)  
 Initial therapy 167  59.4  (50.7-67.2)  .12 
Characteristics No.patients Median survival (mos) 95% CI P3-150Corrected P3-151
Age (years)  
 <65  74  87.2 (64.5-123.9)  
 ≥65  158  51.1  (42.3-63.0)  .0009 .022  
Sex 
 Female  67  107.9  (55.1-150.9) 
 Male  165  58.7  (48.1-65.7)  .0001 
Hepatomegaly 
 Absent  183  66.0  (58.7-72.5) 
 Present  49  34.5  (27-52.7)  .0025 
Splenomegaly3-152 
 Absent  179  64.5  (55.1-70.7) 
 Present  51  51.1  (36.5-69.9)  .15  
Monoclonal IgM (g/L) 
 Lower than 25  92  68.0  (55.1-96.9)  
 At least 25  140  59.4  (49.3-66.8)  .023  .294 
Hemoglobin level (g/dL)3-152 
 Lower than 12  145  49.3 (37.8-59.4)  
 At least 12  73  107.5  (73.3-126.3) .0001  .003  
Platelets (109/L)3-152 
 Fewer than 150  46  40.2  (33.3-51.1)  
 At least 150  167  67.2 (59.4-76.6)  .0001  .003  
Leukocytes (109/L)3-152 
 Fewer than 4  16  41.7 (13.1-58.2)  
 At least 4 and fewer than 10  176  65.7 (55.1-73.3)  
 At least 10  32  50.7  (30.4-69.3) .0057  .250  
PMN count (109/L)3-152 
 Fewer than 1.5  17  28.1  (4.7-49.3)  
 1.5 to 10  193 64.6  (58.7-72.3)  
 More than 10  6  30.4 (7.5-71.3)  .0006  .070  
No. cytopenia3-152 
 0  57 123.9  (73.4-150.9)  
 1  105  60.7  (42.9-67.7) 
 2 or 3  41  34.5  (23.5-48.1)  .0001  
Serum albumin (g/L)3-152 
 Lower than 40  135  49.3  (40.2-58.6) 
 At least 40  59  107.5  (73.3-131.7)  .0001  .003 
β2 microglobulin3-152 
 Up to 3 mg/L  12 111.6  (37.6-126.3)  
 More than 3 mg/L  30  51.1 (42.3-67.7)  .038  
Plasma volume3-152 
 Less than 50 mL/kg 10  150.9  (15-NA)  
 More than 50 mL/kg  46  38.9 (28.1-51.5)  .0128  
Binet staging3-152 
 A  83  87.2 (67.7-122.4)  
 B  28  52.7  (31.6-95.3)  
 C  84 37.6  (28-51.7)  .0001  
Rai staging3-152 
 0 or 1  53 111.6  (72.3-142.5)  
 2  28  67.2  (38.9-122.4) 
 3 or 4  142  51.7  (37.6-61.8)  .0001  
Gobbi staging3-152 
 Low risk  109  72.3  (64.6-90.4)  
 High risk  53  48.3  (33.2-58.8)  .004  
Treatment  
 No initial therapy  65  66.8  (48.3-118.4)  
 Initial therapy 167  59.4  (50.7-67.2)  .12 

PMN, polymorphonuclear; NA, not achieved.

F3-150

P of the presented analysis.

F3-151

Corrected P for the optimal cutpoint (see text).

F3-152

Data were unavailable for some patients.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal